Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Reports Stock Transactions
SEC Form 4 Filing
CEO Benjamin Palleiko of KalVista Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units to cover tax obligations.
Summary
- On June 6, 2024, Benjamin Palleiko, CEO of KalVista Pharmaceuticals, acquired 15,625 shares of common stock through the vesting of restricted stock units.
- Also on June 6, 2024, Palleiko disposed of 15,625 restricted stock units.
- On June 7, 2024, Palleiko sold 7,465 shares of common stock at a weighted average price of $11.5296 to cover tax withholding obligations related to the vesting of the RSUs.
- Following these transactions, Palleiko directly owns 224,547 shares of KalVista Pharmaceuticals common stock and 234,375 restricted stock units.
Sentiment
Score: 5
Explanation: The Form 4 filing is a routine disclosure of stock transactions by a company insider. The transactions appear to be related to tax obligations, and there is no indication of unusual activity.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely to be minimal as it is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Acquisition of 15,625 shares of common stock through RSU vesting and disposal of 15,625 restricted stock units. |
| 06/07/2024 | Sale of 7,465 shares of common stock at an average price of $11.5296. |
| 06/10/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.